Want to see IN:ANUHPHR full AI Analyst Report?
ANUHPHR Stock Chart & Stats
₹77.53
-₹3.95(-1.77%)
At close: 4:00 PM EST
₹77.53
-₹3.95(-1.77%)
Day’s Range― - ―
52-Week Range₹66.72 - ₹93.00
Previous CloseN/A
Volume12.53K
Average Volume (3M)6.00K
Market Cap
₹8.40B
Enterprise Value₹2.83K
Total Cash (Recent Filing)₹135.33M
Total Debt (Recent Filing)₹2.27M
Price to Earnings (P/E)18.6
Beta0.70
Next Earnings
Nov 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.82%
Share Statistics
EPS (TTM)2.00
Shares Outstanding100,224,000
10 Day Avg. Volume6,374
30 Day Avg. Volume5,996
Financial Highlights & Ratios
PEG Ratio-1.25
Price to Book (P/B)1.91
Price to Sales (P/S)0.87
P/FCF Ratio-61.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthSustained expansion in API sales indicates healthy demand and growing commercial scale. Higher volumes can improve manufacturing utilization and strengthen the company’s ability to absorb fixed compliance and production costs over time.
Exceptionally Conservative Balance SheetNear-zero leverage gives Anuh Pharma substantial financial flexibility and reduces refinancing risk. A strong equity and asset base can support capacity investment, withstand industry volatility, and preserve resilience if operating conditions weaken.
Positive Earnings Growth TrendPositive EPS growth shows that the business has generated meaningful earnings expansion despite recent pressure. If sales momentum and operating efficiency recover, this earnings base could support continued financial strengthening.
Bears Say
Material Margin CompressionThe sharp decline in gross and net margins indicates weaker product mix, pricing, or cost absorption. Persistent compression would reduce earnings resilience and limit the benefit of revenue growth unless manufacturing efficiency or pricing power improves.
Negative Operating And Free Cash FlowNegative cash generation despite positive net income signals weaker earnings conversion, potentially from working-capital needs or investment spending. If prolonged, this could constrain internal funding and make reported profitability less dependable.
Earnings Declined Despite Higher SalesFalling net income while revenue rises suggests that incremental sales are currently less profitable. This weak operating leverage raises concerns about product economics and cost control, making future growth less valuable until profitability stabilizes.
Anuh Pharma Limited News
ANUHPHR FAQ
What was Anuh Pharma Limited’s price range in the past 12 months?
Anuh Pharma Limited lowest stock price was ₹66.72 and its highest was ₹93.00 in the past 12 months.
What is Anuh Pharma Limited’s market cap?
Anuh Pharma Limited’s market cap is ₹8.40B.
When is Anuh Pharma Limited’s upcoming earnings report date?
Anuh Pharma Limited’s upcoming earnings report date is Nov 13, 2026 which is in 73 days.
How were Anuh Pharma Limited’s earnings last quarter?
Anuh Pharma Limited released its earnings results on Aug 07, 2026. The company reported ₹1.14 earnings per share for the quarter.
Is Anuh Pharma Limited overvalued?
According to Wall Street analysts Anuh Pharma Limited’s price is currently Overvalued.
Does Anuh Pharma Limited pay dividends?
Anuh Pharma Limited pays a Annually dividend of ₹1.5 which represents an annual dividend yield of 1.82%. See more information on Anuh Pharma Limited dividends here
What is Anuh Pharma Limited’s EPS estimate?
Anuh Pharma Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Anuh Pharma Limited have?
Anuh Pharma Limited has 100,224,000 shares outstanding.
What happened to Anuh Pharma Limited’s price movement after its last earnings report?
Anuh Pharma Limited reported an EPS of ₹1.14 in its last earnings report. Following the earnings report the stock price went up 1.166%.
Which hedge fund is a major shareholder of Anuh Pharma Limited?
Currently, no hedge funds are holding shares in IN:ANUHPHR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Anuh Pharma Limited
Anuh Pharma Ltd. is an Indian enterprise specializing in the manufacturing and distribution of bulk drugs and various chemical compounds. The company provides a comprehensive selection of active pharmaceutical ingredients (APIs), encompassing macrolides, anti-tuberculosis agents, antibacterials, anti-asthmatics, anti-diabetic compounds, intermediates, expectorants, quinolones, anti-malarials, anti-gout medications, antibiotics, anti-platelet drugs, and antihistamines. Additionally, it produces corticosteroids valued for their anti-inflammatory, immunosuppressant, anti-pruritic, and anti-mitotic actions. Anuh Pharma is also engaged in developing new products within therapeutic categories such as coagulants, gastrointestinal treatments, anticonvulsants, and cholesterol-reducing medications. Its products are sold both domestically and to international markets. The company, established in 1960, maintains its headquarters in Mumbai, India.
Technical Analysis
Albert David Ltd
―
Kilitch Drugs (India) Limited
―
Sigachi Industries Limited
―
Wanbury Limited
―
Zim Laboratories Ltd.
―